Cargando…
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705823/ https://www.ncbi.nlm.nih.gov/pubmed/28395525 http://dx.doi.org/10.2217/fon-2016-0504 |